

HIVQUAL-Haiti Adult Indicators and Eligibility for Round 1 Data Collection			
Eligibility: All patients with one visit in the previous 6 month review period.			
Indicator	Definition	Numerator	Denominator
Retention of Patients	Proportion of all patients on ARVs who are regularly followed. During the visit the patient should be seen by either the dispensing nurse, pharmacy, laboratory, nurse or doctor.	The number of patients (all ages) on ART with at least one visit within 3 months of their last visit	The number of patients (all ages) on ART who have been in the program at least 3 months
CD4 Monitoring	Proportion of all patients with a CD4 count at enrollment and at 6 months.	The number of patients (all ages) with a CD4 test at enrollment (within the two months of enrollment) and at 6 months (between two and eight months)	The total number of patients (all ages) enrolled in the program within the preceding 6-12 months
ARV Therapy	The proportion of all eligible patients placed on ART in the past 6 months. ART eligibility is defined by CD4 count (<200), TLC (<1200), WHO Stage III and CD4 <350, or WHO Stage IV.	The number of patients (all ages) enrolled in ARV therapy according to WHO criteria*** in the past 6 months	The number of patients (all ages) eligible for ART during the past 6 months, according to WHO criteria***
Cotrimoxazole Prophylaxis**	The proportion of adults and children living with or exposed to HIV who received cotrimoxazole prophylaxis during the past 6 months. A daily dose of cotrimoxazole is recommended in every HIV positive adult.	The number of patients (>10 years) who have received cotrimoxazole prophylaxis during the past 6 months	The number of patients (>10 years) having received at least one medical visit in the past 6 months
Adherence Assessment	Proportion of all HIV-infected patients on ART having had an adherence evaluation during the past month.	The number of patients on ART (all ages) who have had an adherence assessment (pill-count or questionnaire) during the past 3 months	The total number of patients (all ages) on ART having had at least one medical visit during the past 3 months
TB Screening	The proportion of all HIV-infected patients evaluated for TB at enrollment during the past 6 months. TB screening is done by tuberculin skin test (TST). Patients with greater than or equal to 5 mm would benefit from a chest x-ray to eliminate active TB. If there is no active TB, they should receive a daily dose of INH.	The number of patients (all ages) screened for TB (TST) at enrollment during the past 6 months	The number of HIV patients (all ages) enrolled in care during the past 6 months
Nutrition Evaluation[§]	The proportion of patients (>19 years) who have had a nutritional evaluation during the past 6 months.	The number of patients (>19 years) having had a nutritional evaluation during the past 6 months	The number of HIV patients (>19 years) who have had at least one medical visit during the past 6 months
PMTCT	The proportion of HIV-infected pregnant women who have received ARV prophylaxis during the past 6 months.	The number of HIV-infected pregnant women who have received prophylaxis in the past 6 months	The number of HIV infected pregnant women who are eligible for prophylaxis during the past 6 months

*All patients who have received at least one dispensation of ART drugs at the reporting clinic site

**Cotrimoxazole prophylaxis is recommended for all HIV-infected adults and adolescents

***CD4 <200; TLC <1200; WHO stage III and CD4 <350; or WHO stage IV

[§]**Alternative:** Calculate BMI ($BMI = [wt (lbs) / ht (in)^2] \times 703$, or $wt (kg) / ht (meters)^2$) for all patients with weight recorded in the preceding month, and height recorded: 1) ever for pts age ≥ 19 yrs, 2) in the preceding month for pts age < 19 yrs

HIVQUAL-Haiti Pediatric Indicators and Eligibility for Pediatric Data Collection

Eligibility:

Indicator	Definition	Numerator	Denominator
Cotrimoxazole Prophylaxis	The proportion of HIV-exposed and infected children* having received cotrimoxazole prophylaxis during the past 6 months.	Number of children HIV-exposed and infected children receiving follow up at the clinic that are eligible for and have received cotrimoxazole prophylaxis during the past 6 months	Number of HIV-exposed and infected children receiving follow-up at the clinic during the past 6 months
Immunizations	The proportion of HIV-exposed and infected children who have received appropriate vaccinations	The number of HIV-exposed and infected children under the age of 5 years who have completed their age-appropriate vaccinations during the past 6 months	The number of HIV-exposed and infected children being seen at the clinic during the past 6 months

*Cotrimoxazole prophylaxis is recommended for HIV-exposed and infected children age 6 weeks-12 months (unless HIV infection is ruled out in exposed children age < 12 months); HIV-infected children age 1 to 4 years with WHO stage II, III or IV disease; and HIV-infected children age > 5 yrs regardless of WHO stage. The recommendation for prophylaxis for HIV-infected children age > 5 yrs is new and has not yet been adopted by all sites.